Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

[Analysis of clinical characteristics and JAK2V617F mutation of Tibetan people living at high altitudes with polycythemia].

Tang DJ, Ye YX, Li J.

Zhonghua Xue Ye Xue Za Zhi. 2012 Nov;33(11):960-2. Chinese. No abstract available.

PMID:
23363758
2.

[Clinical study on relationship between protein tyrosine kinase JAK2 V617F mutation and high altitude polycythemia].

Ji LH, Li ZQ, Cui S.

Zhonghua Xue Ye Xue Za Zhi. 2012 Apr;33(4):319-20. Chinese. No abstract available.

PMID:
22781728
3.

Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.

Rossi D, Cortini F, Deambrogi C, Barbieri C, Cerri M, Franceschetti S, Conconi A, Capello D, Gaidano G.

Leuk Res. 2007 Jan;31(1):97-101. Epub 2006 Apr 18.

PMID:
16620973
4.

An EPAS1 haplotype is associated with high altitude polycythemia in male Han Chinese at the Qinghai-Tibetan plateau.

Chen Y, Jiang C, Luo Y, Liu F, Gao Y.

Wilderness Environ Med. 2014 Dec;25(4):392-400. doi: 10.1016/j.wem.2014.06.003. Epub 2014 Sep 16.

PMID:
25239027
5.

Isolated erythrocythemia: a distinct entity or a sub-type of polycythemia vera?

Ohyashiki K, Kiguchi T, Ito Y, Gotoh A, Tauchi T, Miyazawa K, Kimura Y, Hisatomi H, Ohyashiki JH.

Jpn J Clin Oncol. 2008 Mar;38(3):230-2. doi: 10.1093/jjco/hym174. Epub 2008 Feb 21. No abstract available.

PMID:
18292125
6.

Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.

Bernardi M, Ruggeri M, Albiero E, Madeo D, Rodeghiero F.

Am J Hematol. 2009 Apr;84(4):258-60. doi: 10.1002/ajh.21357. No abstract available.

7.

Serum levels of granulocyte colony-stimulating factor in JAK2 V617F-positive vs. negative erythrocytosis.

Fujita H, Hamaki T, Ohwada A, Tomiyama J, Nishimura S.

Int J Lab Hematol. 2011 Dec;33(6):e20-1. doi: 10.1111/j.1751-553X.2011.01336.x. Epub 2011 Jun 6. No abstract available.

PMID:
21645282
8.

Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.

Spolverini A, Pieri L, Guglielmelli P, Pancrazzi A, Fanelli T, Paoli C, Bosi A, Nichele I, Ruggeri M, Vannucchi AM.

Haematologica. 2013 Sep;98(9):e101-2. doi: 10.3324/haematol.2013.090175. Epub 2013 Jun 28. No abstract available.

9.

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.

Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, Mittermüller J, Petrides P, Schlag R, Sandner R, Selbach J, Slawik HR, Tessen HW, Wehmeyer J, Kern W, Haferlach T.

Haematologica. 2009 Mar;94(3):414-8. doi: 10.3324/haematol.13223.

10.

Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.

Strobbe L, Lestrade P, Hermans MH, Fijnheer R.

Ann Hematol. 2007 Nov;86(11):801-3. Epub 2007 Aug 17.

PMID:
17703302
11.

High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera.

Yeh YM, Chen YL, Cheng HY, Su WC, Chow NH, Chen TY, Ho CL.

Am J Clin Pathol. 2010 Aug;134(2):266-70. doi: 10.1309/AJCPK7KGOWPHYWM0.

PMID:
20660330
12.

Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders.

De T, Prabhakar P, Nagaraja D, Christopher R.

J Neurol Sci. 2012 Dec 15;323(1-2):178-82. doi: 10.1016/j.jns.2012.09.012. Epub 2012 Sep 30.

PMID:
23031663
13.

JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera.

Röthlisberger B, Huber A, Bargetzi M, Mendez A, Heizmann M.

Leuk Lymphoma. 2008 Mar;49(3):586-8. doi: 10.1080/10428190701861652. No abstract available.

PMID:
18297539
14.

JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia.

Randi ML, Ruzzon E, Tezza F, Scapin M, Duner E, Scandellari R, Fabris F.

Aging Clin Exp Res. 2011 Feb;23(1):17-21.

PMID:
21499015
15.

JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia.

Wong RS, Cheng CK, Chan NP, Cheng SH, Wong WS, Lau KM, Cheng G, Ng MH.

Br J Haematol. 2008 Jun;141(6):902-4. doi: 10.1111/j.1365-2141.2008.07127.x. Epub 2008 Apr 10. No abstract available.

PMID:
18410451
16.

JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.

Martínez-Avilés L, Besses C, Alvarez-Larrán A, Cervantes F, Hernández-Boluda JC, Bellosillo B.

Haematologica. 2007 Dec;92(12):1717-8.

17.

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.

Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K.

Leukemia. 2007 May;21(5):1103-4. Epub 2007 Feb 15. No abstract available.

PMID:
17301812
18.

JAK2 mutations in Asian patients with essential thrombocythaemia.

Wong GC, Kam GL, Koay ES.

Intern Med J. 2011 Feb;41(2):191-6. doi: 10.1111/j.1445-5994.2010.02199.x.

PMID:
20214695
19.

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.

Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD, Duval A, Maynadié M, Hermouet S.

Haematologica. 2008 Nov;93(11):1723-7. doi: 10.3324/haematol.13081. Epub 2008 Aug 25. Erratum in: Haematologica. 2010 Feb;95(2):344. Vidal, Aurélie [corrected to Duval, Aurélie].

20.

The complete evaluation of erythrocytosis: congenital and acquired.

Patnaik MM, Tefferi A.

Leukemia. 2009 May;23(5):834-44. doi: 10.1038/leu.2009.54. Epub 2009 Mar 19. Review.

PMID:
19295544

Supplemental Content

Support Center